Combined HU and CT-101 treatment inβ-YAC mice.

<p>To determine the effects of combination treatment, in Study 2 we evaluated CT-101 10 mg/kg combined with HU 100 mg/kg, for four weeks. For all graphs n = 12 mice per treatment group. Peripheral blood samples were collected for <b>A)</b> flow cytometry to determine the percentage...

Full description

Saved in:

Bibliographic Details
Main Author:	Mayuko Takezaki (12700243) (author)
Other Authors:	Biaoru Li (628604) (author), Hongyan Xu (29047) (author), Nikhil Patel (2288824) (author), Rudolf Lucas (402664) (author), Ryan E. Cerbone (21354826) (author), Sivanagireddy Koti (21354829) (author), Clifford L. Hendrick (21354832) (author), Louis H. Junker (21354835) (author), Betty S. Pace (12700246) (author)
Published:	2025
Subjects:	Medicine Cell Biology Genetics Molecular Biology Neuroscience Pharmacology Developmental Biology Cancer Hematology similar drug uptake sickle cell disease production occurs leading townes scd mice scd mouse treated hbf protein synthesis fetal hemoglobin expression chemotherapeutic hbf inducers approved fetal hemoglobin subsequent confirmatory studies subsequent studies xlink "> unmet need united states study aimed shortened lifespan point mutation pharmacokinetic parameters peripheral blood organ damage optimal dose occlusive pain novel agent hemorrhagic infarcts findings support demonstrating increases clinical testing clinical severity
Tags:	Add Tag No Tags, Be the first to tag this record!

Combined HU and CT-101 treatment inβ-YAC mice.

Similar Items